Published in

BioMed Central, Journal of Translational Medicine, 1(10), 2012

DOI: 10.1186/1479-5876-10-53

Links

Tools

Export citation

Search in Google Scholar

NF-κB as potential target in the treatment of melanoma

Journal article published in 2012 by Gabriele Madonna, Claudio Dansky Ullman, Giusy Gentilcore, Giuseppe Palmieri ORCID, Paolo Antonio Ascierto
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.